Articles tagged "Immunosuppression"

2019 American Transplant Congress
Effects of Thalidomide and Dexamethasone Co-Treatment on CD8⁺ T Cells
J. Kim¹, E. Kim², Y. Cho¹, H. Lee¹, M. Kim³, Y. Kim³, K. Huh³, B. Kim⁴
¹The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Korea, Republic of, ²Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea, Republic of, ³Department of Transplantation Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of, ⁴Nephrology Division, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
*Purpose: Thalidomide (TM) is known to have anti-cancer and anti-inflammatory effects and dexamethasone (DX) has been reported that it also reduces inflammation and inhibits inflammatory…
2019 American Transplant Congress
Clinical Outcomes of Using mTOR Inhibitors with Reduced Dose of Calcineurin Inhibitors in Lung Transplant Recipients: A Single Center Experience
M. Frawley¹, J. Leedy¹, A. James¹, A. Salter¹, V. Rusanov²
¹Department of Pharmacy, UAB Hospital, Birmingham, AL, ²Division of Pulmonary, Allergy, and Critical Care Medicine, UAB Hospital, Birmingham, AL
*Purpose: The use of mammalian target of rapamycin inhibitors (mTORi) in cardiothoracic transplantation has significantly increased over the past decade. Several recent clinical trials have…
2019 American Transplant Congress
Gut Microbiota May Affect a Variability of Tacrolimus Trough Levels in Kidney Transplant Recipients
J. Kim¹, H. Cho², J. Park³, M. Kwak⁴, B. Kim⁴, J. Lee⁵, D. Kim¹, B. Kim⁶, Y. Kim¹, H. Lee¹
¹Seoul National University Hospital, Seoul, Korea, Republic of, ²Chungbuk National University Hospital, Cheongju, Korea, Republic of, ³Kangwon National University Hospital, Chuncheon, Korea, Republic of, ⁴Chunlab Inc., Seoul, Korea, Republic of, ⁵Seoul National University Boramae Hospital, Seoul, Korea, Republic of, ⁶Hallym University, Chuncheon, Korea, Republic of
*Purpose: The gut microbiota alters expression of drug-metabolizing enzymes and transporters, and consequently affects therapeutic dose and response of medicines. We aimed to investigate the…
2019 American Transplant Congress
Sirolimus in Geriatric Kidney Transplantation: Modification of Outcomes by Pre-Transplant History of Malignancy or Cardiovascular Disease
H. Ibrahim¹, C. Chen², K. Alquadan³, X. Wen⁴, K. L. Womer³, A. H. Santos Jr¹
¹College of Medicine, Div. of Nephrology, Hypertension & Renal Transplantation, Univ. of Florida, Gainesville, FL, ²College of Pharmacy, Univ. of Florida, Gainesville, FL, ³College of Medicine, Div. of Nephrology, Hypertension & Renal Transplantation, Univ. of Florida, Gainesville, FL, ⁴College of Pharmacy, Univ. of Rhode Island, Kingston, RI
*Purpose: We analyzed the outcomes associated with sirolimus (SRL)-regimens in geriatric (>/=65-year-old) kidney transplant recipients (KTRs).*Methods: Using 2000-2016 Scientific Registry of Transplant Recipients data, Cox…
2019 American Transplant Congress
The Use of mTOR Inhibitors Prevents Acute Cellular Rejection in Kidney Transplantation on Belatacept Therapy
J. Shoji, J. C. Leung, Q. Tang, J. P. Roberts, F. Vincenti
University of California San Francisco, San Francisco, CA
*Purpose: Belatacept is a costimulatory blocker that is used as de novo maintenance immunosuppression in kidney transplantation to avoid toxic effects of calcineurin inhibitors and…
2019 American Transplant Congress
Conversion from Calcineurin Inhibitors to Belatacept in Kidney Recipients with Donor-Specific Anti-HLA Antibodies and Calcineurin Inhibitor Nephrotoxicity Decreases the Pathogenicity of Donor-Specific Anti-HLA Antibodies
K. Louis¹, D. Viglietti¹, D. Pievani¹, O. Aubert¹, D. Glotz¹, C. Legendre¹, A. Zeevi², A. Loupy¹, C. Lefaucheur¹
¹Paris Translational Research Center for Organ Transplantation, Paris, France, ²University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Switching from CNI- to Belatacept-based regimen has been associated with improved graft function in low-immunologic risk kidney recipients. We investigated the efficacy and safety…
2019 American Transplant Congress
LCP-Tacrolimus (LCPT; Envarsus XR) Dosing Considerations in De Novo Kidney Transplant Recipients
D. Cibrik¹, P. West-Thielke², S. J. Patel³, D. R. Stevens⁴, U. Meier-Kriesche⁴
¹University of Kansas Medical Center, Kansas City, KS, ²University of Illinois Hospital and Health Sciences System, Chicago, Chicago, IL, ³Veloxis Pharmaceuticals, Cary, NC, ⁴Veloxis Pharmaceuticals Inc., Cary, NC
*Purpose: Different initial dosing strategies were studied in Phase II/Phase III trials evaluating the pharmacokinetics, safety, and efficacy of LCPT in de novo kidney transplantation.…
2019 American Transplant Congress
Utility of AlloSure Monitoring in Simultaneous Kidney and Pancreas Recipients
J. A. Klein, A. Gupta, P. Budhiraja, D. Cibrik
Nephrology, University of Kansas Medical Center, Kansas City, KS
*Purpose: Determine utility and efficacy of donor-derived cell free DNA (dd-cfDNA) monitoring in simultaneous kidney and pancreas (SPK) recipients compared to kidney transplant alone (KTA).…
2019 American Transplant Congress
Clinical Impact of Race and Timing of Acute Rejection on Recipients of Kidney Transplant on Early Steroid Withdrawal Protocol
O. Adebiyi, S. Yaqub, W. Goggins, D. Mishler, T. Taber, A. Sharfuddin
Indiana University, Indianapolis, IN
*Purpose: There has been conflicting reports on the impacts of the timing of acute rejection (AR) (early vs late) on the overall outcome of a…
2019 American Transplant Congress
Long-Term Survival Analysis of Kidney Transplant Recipients Receiving Mizoribine as a Maintenance Immunosuppressant
J. Kim¹, D. Lee¹, J. Oh¹, J. Lee¹, H. Kim¹, Y. Son²
¹Nephrology, Bongseng hospital, Busan, Korea, Republic of, ²Nephrology, Donga University hospital, Busan, Korea, Republic of
*Purpose: It has proved effective as a treatment for lupus nephritis, rheumatoid arthritis, and nephrotic syndrome, after mizoribine was introduced as an immunosuppressive agent to…